<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655015</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS# 18-0056</org_study_id>
    <secondary_id>HSC20180485H</secondary_id>
    <nct_id>NCT03655015</nct_id>
  </id_info>
  <brief_title>Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer</brief_title>
  <official_title>Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Create a living biobank of PDOs from Stage I-III lung cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Creation a living biobank of PDOs from Stage I-IV lung cancer patients (n=50). We selected&#xD;
      enrollment of at least 50 patients so that they can be risk stratified based on lung tumor&#xD;
      type, staging and we plan to store these PDOs in biobank for future experiments. For each&#xD;
      patient, tumor specimens will be collected at time of their surgery. No specific therapeutic&#xD;
      intervention or treatment is provided as part of this study.&#xD;
&#xD;
        1. Establishment and culture of PDOs from lung cancer tumor specimens. PDOs will be&#xD;
           biobanked for future experiments.&#xD;
&#xD;
        2. Lung organoids and CTCs will also be cultured and used to study baseline tumor&#xD;
           characteristics using histology, immunohistochemistry, atomic force measurements; as&#xD;
           well as, oncogenic signaling pathways and proteomic profile of lung organoids and CTCs&#xD;
           derived from lung cancer patients (n&gt;50).&#xD;
&#xD;
        3. Patient demographic information and data to be collected using a patient survey data&#xD;
           sheet with treatment and survival history collected at pre-defined time period per the&#xD;
           protocol schedule.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.</measure>
    <time_frame>10 years</time_frame>
    <description>Establishment of a living biobank of PDOs and the potential of PDOs to repeat their process outside a living organism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of PDO and Circulating tumor cells (CTCs)</measure>
    <time_frame>10 years</time_frame>
    <description>To establish a connection between PDOs and CTCs, and their relationship to cancer</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lung Neoplasm</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lung Tumor Resection</intervention_name>
    <description>Lung Tumor Resection</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patient derived tumor specimens that are cultured into patient-derived organoids (PDOs)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Lung cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Read, consented to and signed the IRB-approved informed consent form prior to any&#xD;
             study related procedure.&#xD;
&#xD;
          -  Diagnosis of lung cancer or lung mass or lymphadenopathy that will undergo tumor&#xD;
             resection as part of standard of care&#xD;
&#xD;
          -  Any clinical stage&#xD;
&#xD;
          -  Adult patients â‰¥18 years of age&#xD;
&#xD;
          -  Able and willing to complete a questionnaire on their environmental/occupational&#xD;
             exposures and smoking/alcohol history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  At the discretion of the treating physician, patient will not be able to fulfill the&#xD;
             requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josephine Taverna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josephine Taverna, MD</last_name>
    <phone>210-450-8234</phone>
    <email>tavernaj@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UT Health San Antonio, M.D. Anderson Cancer Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <email>CTRCReferral@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Josephine Taverna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

